PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institute…
PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein cou…
PHILADELPHIA — (September 12, 2019) — The Wistar Institute has received a grant of approximately $4.6 million from the National Institutes of Health in support of innovative research to tackle antibi…
PHILADELPHIA — (Sept. 6, 2019) — The ARID1A tumor suppressor protein is required to maintain telomere cohesion and correct chromosome segregation after DNA replication. This finding, reported by Wist…
PHILADELPHIA – (SEPT. 4, 2019) – The Wistar Institute, an international leader in biomedical research in cancer, immunology, infectious diseases, and vaccine creation, and IMV Inc. (Nasdaq: IMV; TSX…
PHILADELPHIA — (Aug. 21, 2019) — Contrary to the long-held view that semen can only act as a way to transmit HIV-1 from men to women, scientists at The Wistar Institute and the University of Puerto R…
PHILADELPHIA — (July, 9, 2019) — Currently, no cure for HIV/AIDS exists, but more than 30 years of scientific advancements in treatment and care made possible because of basic research and clinical t…
PHILADELPHIA — (July 3, 2019) —The Wistar Institute, an international leader in biomedical research on cancer, immunology and infectious disease, has received more than $4.2 million in non-federal fu…
PHILADELPHIA — (July, 2, 2019) — The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease and vaccine research, announces the appointment of Rahul S…
PHILADELPHIA — (May 22, 2019) — New research from The Wistar Institute sheds light on the function of the ARID1A protein, encoded by a gene that is among the most frequently mutated across human canc…
